Sponsors (11)
The bill increases affordability and coverage options for many Americans—especially low- and middle-income households and people with chronic conditions—through expanded subsidies, reinsurance, and antitrust enforcement funding, but it does so at significant federal cost, with implementation uncertainty and by removing a drug-pricing negotiation provision that could raise Medicare drug spending.
Low- and middle-income households will see lower monthly premiums because the bill expands premium tax credits (removes the 400% income cap and smooths the subsidy scale) and fixes the 'family glitch' so more spouses and children qualify for subsidies.
People buying individual market plans (including uninsured individuals who gain coverage) will likely see more stable premiums and broader plan availability because the bill creates a federally funded reinsurance program ($10B/year for 2028–2030) that pools high-cost risks nationally.
Uninsured people and patients with chronic conditions could gain new coverage options and more affordable care if the bill enables a publicly administered health plan and uses its negotiation leverage to lower drug and service prices.
Taxpayers could face materially higher federal costs because the bill funds expanded subsidies, a temporary reinsurance program, and new DOJ/FTC enforcement resources—adding multi‑billion dollar obligations and ongoing budget pressure.
Medicare beneficiaries and patients with chronic conditions may pay higher prescription drug costs because the bill removes an existing statutory negotiation provision that could otherwise lower drug prices.
Some patients (especially Medicare Exchange enrollees and those with complex needs) could lose provider options because enforcement or equal-treatment requirements may prompt some providers or practices to stop accepting certain plans, narrowing networks.
Based on analysis of 8 sections of legislative text.
Creates a Medicare-style public plan, expands premium tax credits (including a "family glitch" fix), funds nationwide reinsurance and antitrust enforcement, and removes a Medicare drug-negotiation subsection.
Introduced December 4, 2025 by Michael F. Bennet · Last progress December 4, 2025
Creates a new Medicare-style public health plan and changes rules to expand affordability of individual market coverage, while funding a nationwide reinsurance program and increased antitrust work. It also changes premium tax credit rules (removing a 400% cap language, introducing a new sliding scale, and fixing the "family glitch"), makes providers who limit patient acceptance subject to exclusion unless they treat plan enrollees equally, and strikes a subsection of the Medicare drug negotiation law. The bill authorizes multiyear appropriations for reinsurance and antitrust enforcement and requires two reports to Congress on antitrust activities and market impacts.